P11-05
Exploring unexpected factors related to glaucoma onset in diabetes patients using LIFE Study data
Kaito SASAKI *1, Qiao HE2, Koichiro KATO1, 4, Haruhisa FUKUDA3
1Department of Applied Chemistry, Graduate school of Engineering, Kyushu University
2Department of Systems Life Sciences, Graduate School of Systems Life Sciences, Kyushu University
3Department of Health Care Administration and Management, Graduate school of Medical science, Kyushu Universit
4Center for Molecular Systems, Kyushu University, Kyushu University
( * E-mail: sasaki.kaito.864@s.kyushu-u.ac.jp )
It is generally said that glaucoma is one of the main cause of blindness in Japan. According to the survey from Japan Glaucoma Society (JGS), one in twenty people over 40 years old suffers from glaucoma. In addition, nine out of ten glaucoma patients don’t go to ophthalmology and are not cured. This means older people are vulnerable to glaucoma and its patients are difficult to be aware of its symptoms. One of the main reasons why glaucoma patients have difficulty in recognizing its sign is that progress of glaucoma is slow. Appearance of invisible places and narrowing visible field are the typical symptoms of glaucoma. The symptoms slowly emerge, and the patients are hard to notice them in the initial phase. Thus, most glaucoma patients take delay treatment of glaucoma and in some case, become blindness. Moreover, although glaucoma patients receive proper treatments, symptoms of glaucoma can’t improve completely. The purpose of treatment is to stop or slow the progress of glaucoma, not to restore vision. On the other hand, various diseases and medications are found to be associated with the development of glaucoma. In particularly, a meta-analysis shows a strong association with the development of glaucoma and diabetes. It is estimated that there are approximately 10 million diabetes patients in Japan. As mentioned above, its patients are more likely to contract glaucoma than non-diabetics. In contrast, there are patients with diabetes who do not develop glaucoma. The factors that influence this difference are currently unknown. Therefore, to improve quality of life of diabetics and curtail medical expenses towards glaucoma treatments, it is significant to identify the factors that affect the development of glaucoma among diabetic patients. In this study, we will conduct a data-driven study using the LIFE Study data, a database that integrates health-related data on health, medical care, long-term care, and administration held by local governments on a per-resident basis, to identify factors correlated with the development of glaucoma in diabetic patients. We extracted diabetes patients during 2017-2018 from specific health checkups dataset based on the definition of inspection values (fasting blood pressure ≧ 126 mg/dL and HbA1c ≧ 6.5%) and medication of diabetes drug. Each extracted patient was tied to specific health checkup information (blood pressure, cholesterol level etc.) for explanatory variable and labeled with the presence or absence of glaucoma developement for the objective variable. A model was then constructed to classify whether or not the patient developed glaucoma using LightGBM and SHAP (one of the explainable AI methods). Analysis of the predictive rationale for the classification model suggested an association between low HbA1c and glaucoma development. In addition to this analysis, factor exploration is also underway in survival analysis methods.